With a continued and visible growth, Seattle Genetics Company is currently one of the leading companies in antibody technologies with its renowned antibody-drug conjugate (ADC). The brain behind this successful company is none other than Clay Siegall who is the Co-Founder, President, Chief Executive Officer and a Member of the Board of Directors of the Company.
The company was founded in 1998 and has been in operation all through. This iconic figure in the medical industry has guided the company to raise more than $330 million through public and various private holding and also in the 2001 Initial Public Offering. Under his leadership, the Company has come into various internal and international collaborations agreement like with Genentech, MedImmune, CuraGen, and Bayer.
Seattle Genetics’ global headquarters are at Bothell Cascade Business Park where the focus is the human antibodies. All the studies, research, packaging of drugs and manipulating are towards human antibodies. The power behind their antibodies is their connection to therapy which strengthens the antibody to destroy the target cancer cell from the inside. This strategy could be the entrance to the big league’s planet. One outstanding achievement of Seattle Genetics is it’s consistent despite the problems that have been influencing pharmaceutical companies which even led to the closure of some like Immunex.
Having great ambitions of becoming one of the great Pharms, it leads the Washington health sectors for being one of the biggest biotech, thanks to the contributions of Clay Siegall. The net worth of the company is ranging to almost $10 billion and a population of around 900 employees who are expected to rise to 1,100 as the end elapses. With the current flagship drug of Seattle Genetics called Adcetris, which is projected to be a treatment of lymph cancer, the company will emerge to be a worldwide, multiproduct, and oncology company.
One of the greatest attention of the company is ADC which basically targets at antigens-protein molecules which are used by the immune system so as to produce antibodies. The company is expected to present more discoveries because of its able CEO. Siegall has served in many health companies which are inexhaustible.
He served as the Senior Research Officer at Bristol-Myers Squibb Pharmaceutical Research Institute, as Non-Executive Director at Mirno Therapeutics and many others. He has authored around 67 scientific papers and journals. He has received Pierce Award and even Entrepreneur of the Year by Ernst Young. He received B.S. in Zoology at the University of Maryland and Ph.D. in Genetics at George Washington University.